Current (but Not Actively Recruiting) / Recently Completed Trials
ADROIT (Abbott DBS Registry of Outcomes for Indications over Time)
Intended to collect long-term safety and effectiveness data on various populations implanted with FDA approved Abbott DBS systems as part of clinical care.
Primary Investigator: Paolo Moretti, MD
Sub-Investigators: Shervin Rahimpour, MD, Meghan Zorn, PA, Jumana Alshaikh, MD, Panagiotis Kassavetis, MD, PhD, John Steffens, MD
CYClical Lower Extremity Exercise for Parkinson's Trial (CYCLE Trial) | National Institutes of Health
Determining the effectiveness of two different types of aerobic exercise, forced and voluntary, on motor and non-motor performance in individuals with Parkinson’s disease.
Sub-Investigator: Paolo Moretti, MD
Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN) Phase 2 |National Institutes of Health
The overall goals of this project are to help adults and children with undiagnosed disease, spread across ~10% of the Continental US, get access to unprecedented diagnostic and care resources.
Primary Investigator: Lorenzo Botto, MD
Sub-Investigator: Paolo Moretti, MD
M20-098: An Open-Label Extension of Studies M15-736 and M20-339 Evaluating the Safety and Tolerability of ABBV-951 | Abbvie, Inc.
Abbv-951 is a new formulation of carbidopa/levodopa developed for continuous subcutaneous infusion. Abbvie, Inc.
Primary Investigator: Paolo Moretti, MD
Sub-Investigators: Meghan Zorn, PA, Guillaume Lamotte, MD, MSc, Perla Thulin, MD
M20-339: Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients | Abbvie, Inc.
A twelve-day period of the trial took place in hospital confinement with 24-hour continuous infusion and monitoring. Abbvie, Inc.
Primary Investigator: Paolo Moretti, MD
Sub-Investigators: Meghan Zorn, PA, Guillaume Lamotte, MD, MSc, Perla Thulin, MD
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety, and Tolerability of ABBV-951 Continuous Subcutaneous Infusion in Abdomen to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients | Abbvie, Inc.
Primary Investigator: Paolo Moretti, MD
Sub-Investigator: Meghan Zorn, PA
PD0053 | UCB Pharma Inc.
A double-blind, placebo-controlled, randomized, 18-month phase 2A study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral UCB0599 in study participants with early Parkinson’s disease UCB Pharma Inc. Aim to try and slow the progression of the disease and symptoms by preventing the clumping of Lewy bodies in the brain and stopping their spread from cell to cell.
Primary Investigator: Paolo Moretti, MD
Sub-Investigators: Meghan Zorn, PA, Guillaume Lamotte, MD, MSc, Perla Thulin, MD and Jumana Alshaikh, MD
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's Disease
Primary Investigator: Paolo Moretti, MD
Sub-Investigator: Meghan Zorn, PA
A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease | NIH/NINDS
To determine the optimal dose frequency of light therapy to improve sleep and other non-motor symptoms in Parkinson’s disease. Results from the study will guide in further development of light therapy for PD.
Primary Investigator: Paolo Moretti, MD
Sub-Investigator: Perla Thulin, MD
SynOne Study
The Synuclein-One Study evaluates a-synuclein in patients with Parkinson’s disease, Multiple System Atrophy, Dementia with Lewy bodies, and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Primary Investigator: Guillaume Lamotte, MD, MSc
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson’s Disease with and without Orthostatic Hypotension: A Cross-Over Study
Levodopa is the most common medication used to treat the symptoms of Parkinson’s disease. Research is needed for us to better understand how Levodopa affects the blood pressure and heart rate in patients with Parkinson’s disease.
Primary Investigator: Guillaume Lamotte, MD, MSc
Genetics of Parkinson’s Disease
Major goals: Analysis of multi-generation families with an excess of Parkinson’s disease to identify disease predisposition genes.
Primary Investigator: Dr. Cannon-Albright
Co-Investigators: Paolo Moretti, MD and Stefan Pulst, MD, Dr. med
KinectHD: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington Disease | Neurocrine Biosciences, Inc.
Primary Investigator: Meghan Zorn, PA
.png)
.png)
